Patent Examiner Noble E. Jarrell
Art Unit 1699 · Drug Compounds, Formulations, Agrochemicals & Microorganisms · Tech Center 1600 · 280 applications filed 2021–2026
Noble E. Jarrell is a USPTO patent examiner in Art Unit 1699 (Drug Compounds, Formulations, Agrochemicals & Microorganisms) with 280 applications from filing years 2021–2026. Examiner Jarrell's allowance rate is 72.7%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 70% of examiners. In 2021, decided applications with an examiner interview were allowed 28.2 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1699 · Drug Compounds, Formulations, Agrochemicals & Microorganisms
- Title / gradePrimary Patent Examiner · GS-14
- Service23 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsJARRELL, NOBLE E
Examiner Jarrell can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Jarrell
- The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 28.2 to 40.6 points.
- Plan for the timeline. First office action averages 935 days vs the 623-day USPTO norm.
- Expect a §112. Definiteness & disclosure is the most-issued rejection (109), and applicants overcame it 78.8% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 25.9 to 31.9 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeApplicants overcame 52 of the 66 decided §112 definiteness & disclosure rejections from Examiner Jarrell in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Jarrell?
Draft your response with Examiner Jarrell's record and Art Unit 1699's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response tools in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 16.3% | 100.0% | 59.4% | +40.6pp |
| 2022 | 17.7% | 100.0% | 71.4% | +28.6pp |
| 2021 | 24.1% | 92.3% | 64.1% | +28.2pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Jarrell.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 17.7% | 100.0% | 74.1% | +25.9pp |
| 2021 | 17.2% | 100.0% | 68.1% | +31.9pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/598629 | Aurora Kinase Inhibitors for Inhibiting Mitotic Progression | Patented | 0 | 🔒 View |
| 18/516585 | Crystalline Polymorphs of a Muscarinic Acetylcholine Receptor Agonist | Patented | 1 | 🔒 View |
| 18/273956 | Administration Method of a Chemotherapeutic Agent | Patented | 1 | 🔒 View |
| 19/388266 | Ras Inhibitors | Patented | 1 | 🔒 View |
Art Unit 1699 technology
Frequently asked questions
What is Examiner Noble E. Jarrell's allowance rate?
Is Examiner Jarrell a hard examiner?
Do examiner interviews help with Examiner Jarrell?
What is Examiner Jarrell's most common rejection?
Is an RCE worth filing with Examiner Jarrell?
How long until the first office action from Examiner Jarrell?
How do I contact Examiner Noble E. Jarrell?
Put Examiner Jarrell's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.